About the Company
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
62
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $OYST News
IPO Outlook For The Week: Chinese Media, Chinese Real Estate, Dry-Eye Therapy
Oyster Point Pharma, Inc. (NASDAQ: OYST) will issue 5 million shares between $16 and $18 Thursday on the Nasdaq. The offering represents 24.3% of outstanding shares and is expected to raise about ...
Oyster Point Pharma Announces Expanded Patient Access to TYRVAYA®
Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and ...
Alumni Association Award Winners
He was previously CEO of Oyster Point Pharma (NASDAQ: OYST), where he led the company through ... before overseeing the company’s acquisition by Viatris Inc. in 2023. Under his leadership, Oyster ...
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named ...
Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?
Viatris Inc. Price, Consensus and EPS Surprise Viatris ... VTRS completed the acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new division, Viatris Eye Care.
David M Mott's Net Worth
Who is David M Mott? David M Mott has an estimated net worth of $2.21 Billion. This is based on reported shares across multiple companies, which include PhaseBio Pharmaceuticals Inc, Ra ...
Peter W. Sonsini's Net Worth
Who is Peter W. Sonsini? Peter W. Sonsini has an estimated net worth of $898 Million. This is based on reported shares across multiple companies, which include Desktop Metal, Inc., Cascadian ...
HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s ...
Lantern Pharma Inc. (LTRN)
DALLAS, April 22, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and ...
INZY Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases.
FSD Pharma Inc. (HUGE)
TORONTO, ON / ACCESSWIRE / April 22, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu ...
Biomarin Pharmaceutical Inc BMRN
We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...
Loading the latest forecasts...